Head and Neck Cancer

Regulatory filing completed in Europe for Advexin gene drug

Published in Gene Therapy Weekly, September 12th, 2002

Introgen Therapeutics, Inc., (INGN) announced plans to file an application for its adenoviral p53 product candidate, Advexin, with the European Agency for the Evaluation of Medicinal Products (EMEA).

Advexin is a treatment for head and neck cancer. The EMEA is the European regulatory organization responsible for the approval of new drugs and biologics in Europe and is the European equivalent of the United States Food and Drug Administration (FDA). Currently, Introgen is enrolling head and neck cancer patients in two global phase 3 clinical trials in the United States and Europe.

Introgen also announced that the European filing will be submitted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-09-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry